FDA approves Sanofi and Regeneron's skin cancer med

Oct. 2, 2018

Libtayo, the skin cancer drug made by Sanofi and Regeneron, has been approved by the U.S. Food and Drug Administration.

The med is used to treat metastatic cutaneous squamous cell carcinoma, a rare skin cancer, in patients whose condition have not improved following surgery or chemotherapy.

Sanofi Genzyme and Regeneron will market the drug jointly in the U.S., selling at a list price of $9,100 for a three-week treatment cycle.

Read the Reuters report